Literature DB >> 9673224

Roles of innate and adaptive immunity in respiratory mycoplasmosis.

S C Cartner1, J R Lindsey, J Gibbs-Erwin, G H Cassell, J W Simecka.   

Abstract

Current evidence suggests that host defense in respiratory mycoplasmosis is dependent on both innate and humoral immunity. To further delineate the roles of innate and adaptive immunity in antimycoplasmal defenses, we intranasally infected C3H/HeSnJ-scid/scid (C3H-SCID), C3H/HeSnJ (C3H), C57BL/6J-scid/scid (C57-SCID), and C57BL/6N (C57BL) mice with Mycoplasma pulmonis and at 14 and 21 days postinfection performed quantitative cultures of lungs and spleens, quantification of lung lesions, and histopathologic assessments of all other major organs. We found that numbers of mycoplasmas in lungs were associated with genetic background (C3H susceptible, C57BL resistant) rather than functional state of adaptive immunity, indicating that innate immunity is the main contributor to antimycoplasmal defense of the lungs. Extrapulmonary dissemination of mycoplasmas with colonization of spleens and histologic lesions in multiple organs was a common occurrence in all mice. The absence of adaptive immune responses in severe combined immunodeficient (SCID) mice resulted in increased mycoplasmal colonization of spleens and lesions in extrapulmonary sites, particularly spleens, hearts, and joints, and also reduced lung lesion severity. The transfer of anti-M. pulmonis serum to infected C3H-SCID mice prevented extrapulmonary infection and disease, while the severity of lung lesions was restored by transfer of naive spleen cells to infected C3H-SCID mice. Collectively, our results strongly support the conclusions that innate immunity provides antimycoplasmal defense of the lungs and humoral immunity has the major role in defense against systemic dissemination of mycoplasmal infection, but cellular immune responses may be important in exacerbation of mycoplasmal lung disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673224      PMCID: PMC108377     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

Review 1.  Immunity to mycoplasma infections of the respiratory tract: a review.

Authors:  G Taylor
Journal:  J R Soc Med       Date:  1979-07       Impact factor: 5.344

2.  Interaction of Mycoplasma pneumoniae with alveolar macrophages: viability of adherent and ingested mycoplasmas.

Authors:  P Erb; W Bredt
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages.

Authors:  J M Hickman-Davis; J R Lindsey; S Zhu; S Matalon
Journal:  Am J Physiol       Date:  1998-02

4.  Detection of antibodies to Mycoplasma pulmonis by an enzyme-linked immunosorbent assay.

Authors:  S A Horowitz; G H Cassell
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

5.  Arthritis caused by Mycoplasma salivarium in hypogammaglobulinaemia.

Authors:  A K So; P M Furr; D Taylor-Robinson; A D Webster
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

6.  Protection of mice against Mycoplasma pulmonis infection using purified mouse immunoglobulins: comparison between protective effect and biological properties of immunoglobulin classes.

Authors:  G Taylor; C J Howard
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

7.  Intracage ammonia promotes growth of Mycoplasma pulmonis in the respiratory tract of rats.

Authors:  T R Schoeb; M K Davidson; J R Lindsey
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

8.  Effect of T-cell deficiency on the chronicity of arthritis induced in mice by Mycoplasma pulmonis.

Authors:  E C Keystone; D Taylor-Robinson; M F Osborn; L Ling; C Pope; V Fornasier
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

9.  Primary late-onset hypogammaglobulinaemia associated with inflammatory polyarthritis and septic arthritis due to Mycoplasma pneumoniae.

Authors:  C L Johnston; A D Webster; D Taylor-Robinson; G Rapaport; G R Hughes
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

10.  Interactions between murine alveolar macrophages and Mycoplasma pulmonis in vitro.

Authors:  J K Davis; K M Delozier; D K Asa; F C Minion; G H Cassell
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  36 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  The complete genome sequence of the murine respiratory pathogen Mycoplasma pulmonis.

Authors:  I Chambaud; R Heilig; S Ferris; V Barbe; D Samson; F Galisson; I Moszer; K Dybvig; H Wróblewski; A Viari; E P Rocha; A Blanchard
Journal:  Nucleic Acids Res       Date:  2001-05-15       Impact factor: 16.971

3.  Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite.

Authors:  J Hickman-Davis; J Gibbs-Erwin; J R Lindsey; S Matalon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against mycoplasma respiratory disease.

Authors:  Sheetal Bodhankar; Xiangle Sun; Matthew D Woolard; Jerry W Simecka
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

5.  Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis.

Authors:  Lina Fassi Fehri; Pascal Sirand-Pugnet; Géraldine Gourgues; Gwenaël Jan; Henri Wróblewski; Alain Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Mycoplasma pulmonis Vsa proteins and polysaccharide modulate adherence to pulmonary epithelial cells.

Authors:  Jeffrey R Bolland; Kevin Dybvig
Journal:  FEMS Microbiol Lett       Date:  2012-04-10       Impact factor: 2.742

7.  Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation.

Authors:  Peter Baluk; Alicia Adams; Keeley Phillips; Jennifer Feng; Young-Kwon Hong; Mary B Brown; Donald M McDonald
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

8.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  A novel IL-17-dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection.

Authors:  Amy N Sieve; Karen D Meeks; Sheetal Bodhankar; Suheung Lee; Jay K Kolls; Jerry W Simecka; Rance E Berg
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

10.  NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.

Authors:  Sheetal Bodhankar; Mathew D Woolard; Xiangle Sun; Jerry W Simecka
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.